

Biocon commissions new facility in Bengaluru, launches new device

fe Bureau

Bengaluru, Sept 15: Biocon, a biopharmaceuticals company on Tuesday commissioned a new facility for manufacturing new generation devices for its insulins portfolio.

The company also launched Basalog One, a ready-to-use insulin glargine disposable pen for better blood sugar management for people with diabetes, manufactured in this facility, which is spread over 100,000 square feet area.

“The introduction of Basalog One further strengthens our existing Basalog portfolio comprising vials, refills and reusable devices thus enabling us to offer a comprehensive diabetes management solution for people with diabetes,” Biocon said in a statement.

Kiran Mazumdar-Shaw, chairperson & managing di-



Biocon chairperson and MD Kiran Mazumdar-Shaw

rector, Biocon, said: “Our aim is to provide insulin products to at least one in five insulin-dependent diabetes patients, anywhere in the world. This new devices facility is a key milestone in our journey towards that goal.”

Biocon will be providing basal insulin glargine pen in India first and introduce in global markets, subsequently, she said.

Dr Arun Chandavarkar, CEO & joint managing director, Biocon, said: “India has the potential to become the next global manufactur-

ing hub in biomedical devices and at Biocon, we are committed to explore this potential.”

The global insulin delivery devices market, estimated at \$9.4 billion in 2014, is expected to grow at a CAGR of 7% to reach an estimated \$14.1 billion in 2020.

Biocon has collaborated with Becton Dickinson & Co. (BD), a global medical devices company based in the US, to specially customise the design of this device to enable it to deliver Biocon’s range of insulin products.